Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:57:01 EDT Sat 21 Jun 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:INKT - MINK THERAPEUTICS INC - http://www.inktomi.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INKT - Q0.57.14·8.080.17.26-0.1916-2.63.3202337.11  7.3418  7.1113.79  4.560116:04:11Jun 1015 min RT 2¢

Recent Trades - Last 10 of 233
Time ETExPriceChangeVolume
16:04:11Q7.25-0.181
16:04:11Q7.25-0.181
16:00:03Q7.25-0.1816
16:00:03Q7.25-0.1819
16:00:01Q7.25-0.186
15:59:44Q7.295-0.1351
15:58:02Q7.33-0.107
15:58:02Q7.33-0.1010
15:58:02Q7.33-0.105
15:57:29Q7.295-0.1351

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-10 13:33U:INKTNews ReleaseMiNK Therapeutics Announces Virtual Annual Shareholders Meeting
2025-06-02 09:29U:INKTNews ReleaseMiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
2025-05-15 07:30U:INKTNews ReleaseMiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
2025-05-05 12:30U:INKTNews ReleaseMiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
2025-03-18 07:30U:INKTNews ReleaseMiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
2025-03-04 07:30U:INKTNews ReleaseMiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
2025-02-24 08:30U:INKTNews ReleaseMiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
2025-02-20 07:30U:INKTNews ReleaseMiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
2025-02-12 13:00U:INKTNews ReleaseMiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
2025-01-23 14:13U:INKTNews ReleaseMiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
2024-12-18 09:46U:INKTNews ReleaseMiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
2024-11-14 07:00U:INKTNews ReleaseMiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
2024-11-11 07:30U:INKTNews ReleaseMiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
2024-11-07 10:00U:INKTNews ReleaseMiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
2024-10-31 09:15U:INKTNews ReleaseMiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
2024-10-08 07:30U:INKTNews ReleaseMiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
2024-10-04 09:10U:INKTNews ReleaseMiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
2024-09-03 07:30U:INKTNews ReleaseMiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
2024-08-13 07:00U:INKTNews ReleaseMiNK Reports Second Quarter 2024 Results and Business Update
2024-08-01 07:30U:INKTNews ReleaseMiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report